Establishing Information Analytics as a Core Business Using KIBIT

「これまで主に製薬企業やアカデミアでの創薬研究において、疾患と標的分子との未知の関連性の探索や、メカニズム（作用機序）の仮説生成などを中心に活用され、さらに現在は多様な領域の企業などにおける活用が広がっています。」

「The AI solutions business exceeded the legal tech AI business in operating profit for the first time, making our growth drivers clearer.」

「As a result, revenue for the AI solutions business as a whole was ¥2,797.845 million, up 51.2% year on year, exceeding the initial plan.」

「While the use of AI for compound discovery and optimization is progressing in the upstream stages of the drug discovery process, applying AI to target molecule discovery, which requires advanced natural language processing technology, has remained a challenge.」

「As a result, revenue for the AI solutions business as a whole was ¥1,856.000 million, up 31.7% year on year, exceeding the initial plan.」

「On 12 July 2023, we began the “Drug Discovery AI Factory” business, or DD-AIF.」

「In the AI drug discovery area of the life sciences AI field, we prepared to launch the “Drug Discovery AI Factory” business, or DD-AIF, during the cumulative first-quarter period. The business began operations on 12 July 2023.」

「In the Medical Intelligence area of life sciences AI, we worked to expand the drug discovery business through 3 applications: Amanogawa, which streamlines literature searches; Cascade Eye, which visualizes relationships among molecules and genes; and liGALILEO, which scores complex evaluation metrics, including the scientific validity of target molecules. In December 2022, we also began collaborating with Springer Nature, a global academic publisher, to launch a new literature analysis service using Amanogawa.」

「We position as the AI drug mining business an operation in which our AI discovers drug discovery seeds in an entirely new way from among the millions of compounds existing in Japan, and expect it to expand as a business going forward.」

「In the life sciences AI field, revenue increased year on year due to milestone fees received as clinical trials for the conversational AI program supporting dementia diagnosis progressed smoothly in the Medical Device area, and steady adoption of the Amanogawa AI literature search system by pharmaceutical companies in the Medical Intelligence area. Commercialization also progressed steadily as a new core business.」

「In the life sciences AI field, partnerships with multiple major companies accelerated, and commercialization progressed steadily as a new core business. Revenue increased year on year due to milestone fees received as clinical trials for the conversational AI program supporting dementia diagnosis progressed smoothly, as well as steady adoption of the Amanogawa AI literature search system by pharmaceutical companies.」

「In the life sciences AI field, partnerships with multiple major companies accelerated, and commercialization progressed steadily as a new core business. The receipt of milestone fees from major projects and the adoption of the Amanogawa AI literature search system by academic institutions, in addition to pharmaceutical companies, made significant contributions to the year-on-year increase in revenue.」

「As a result, revenue increased 61.7% year on year to ¥1,443.307 million. Operating loss narrowed to ¥2.139 million, compared with an operating loss of ¥215.635 million in the same period a year earlier, as revenue increased 61.7% year on year, resulting in performance above the previous year.」

「Adoption of KIBIT products progressed in manufacturing and other fields, in addition to the financial sector, where IT investment remained solid. The number of companies adopting AI products reached 237, or 1.2 times the previous year. As a result, revenue increased 29.0% year on year to ¥771.892 million.」

「The number of companies adopting AI products reached 224, or 1.2 times the previous year, marking steady progress in adoption.」

「Although the number of companies adopting AI products rose to 218, up 1.2 times year on year, the growth rate was below expectations.」

「AI product adoption is progressing among some major customers, but as the market is now entering the full-scale adoption phase, preparing for and deciding on full-scale implementation is taking longer than when beginning a proof-of-concept. As a result, the growth rate of the AI solutions business in the third quarter was below expectations, although we do not believe this will affect the medium- to long-term outlook.」

「As a result of strong performance in the business intelligence and healthcare fields in Japan, the cumulative number of companies adopting our AI products rose to 203, or 1.6 times the previous year, while total segment revenue grew substantially, increasing 49.0% year on year.」

「As a result of strong performance in the business intelligence and healthcare fields in Japan, the number of companies adopting our AI products rose to 184, or 1.6 times the previous year, while total segment revenue remained solid, increasing 88.2% year on year.」

「In the AI solutions business, which is a recurring-revenue business, the number of companies adopting KIBIT products rose to 176, up 2.2 times year on year. Total segment revenue increased 56.7% year on year, reaching a record high on the back of growing corporate interest in AI investment, and the business achieved its first full-year operating profit.」

「In the AI solutions business, which is a recurring-revenue business, the number of companies adopting KIBIT products rose to 144, while total segment revenue remained solid, increasing 25.0% year on year. We achieved the No. 1 share of Japan's AI language analysis market for 3 consecutive years from fiscal 2016 (ITR Market View: AI Market 2018; fiscal 2018 is a forecast).」

「In the AI solutions business, which is a recurring-revenue business, the number of companies adopting KIBIT products rose to 121, while total segment revenue remained solid, increasing 39.3% year on year.」

「In the AI solutions business, which is a recurring-revenue business, the number of companies adopting KIBIT products rose to 90, while total segment revenue remained solid, increasing 43.6% year on year.」

「As a result, the number of companies adopting our AI solutions business, which is a recurring-revenue business, rose to 78, while total segment revenue grew substantially to 2.9 times the previous fiscal year's level, and we achieved quarterly operating profits in the third and fourth quarters.」

「As a result, revenue for the AI business segment as a whole in the third quarter was 5 times the level of the same quarter a year earlier, substantially surpassing the previous record, and we achieved our first quarterly operating profit.」

「In the AI business, adoption of KIBIT-equipped products progressed across the business intelligence, healthcare and digital communications fields, and revenue in the AI business segment reached a record high, tripling year on year.」

「In the business intelligence field, we focused on meeting RegTech demand for rapidly improving operational accuracy through the use of AI in response to various regulations, including the Financial Instruments and Exchange Act. We achieved significant results during the first quarter, including decisions by 9 financial institutions to use our solutions, giving us firm confidence in our ability to address this demand.」

「In the AI business, the number of companies adopting software leveraging KIBIT in the business intelligence and digital communications fields increased 2.3 times year on year to 45, while revenue grew 2.4 times year on year. It was a year in which we gained firm confidence in the versatility of KIBIT as artificial intelligence, as companies across a broad range of industries, including manufacturing, finance, retail and distribution, were able to use it effectively to improve operational efficiency.」

「In the business intelligence field, we announced in December 2016 the provision of a business transformation solution specializing in financial institutions. By having specialist staff use KIBIT to analyze daily sales reports, we support financial institutions in improving sales efficiency on both the defensive and offensive fronts, including identifying customer issues and needs and encouraging sales representatives to make proposals aligned with customers' level of understanding and investment experience.」

「In the AI business, customer adoption of various systems in the business intelligence field is progressing steadily, while projects in the healthcare and digital marketing fields are also advancing consistently, expanding the business foundation.」

「In the new business leveraging artificial intelligence technology, the development and marketing of KIBIT, our proprietary artificial intelligence engine, are expanding across 3 areas: healthcare, digital marketing and business intelligence.」

「Meanwhile, the new business areas leveraging artificial intelligence technology are currently being launched, and we will focus on building the structure needed to grow them into pillars of our future business development.」